Teva Pharmaceutical Industries (TEVA) Tops Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Join SI Premium – FREE
Teva Pharmaceutical Industries (NASDAQ: TEVA) reported Q3 EPS of $1.25, $0.02 better than the analyst estimate of $1.23. Revenue for the quarter came in at $4.34 billion versus the consensus estimate of $4.54 billion.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Teva shares Phase 3 data on once-monthly schizophrenia injection
- Teva Pharma (TEVA) call put ratio 1.7 calls to 1 put as share price down 0.79%
- Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophren
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
